Lymphocytes T CD8+ : Questions médicales fréquentes
Nom anglais: CD8-Positive T-Lymphocytes
Descriptor UI:D018414
Tree Number:A15.382.490.555.567.569.220
Termes MeSH sélectionnés :
Probability
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lymphocytes T CD8+ : Questions médicales les plus fréquentes",
"headline": "Lymphocytes T CD8+ : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lymphocytes T CD8+ : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-18",
"dateModified": "2025-02-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lymphocytes T CD8+"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lymphocytes T",
"url": "https://questionsmedicales.fr/mesh/D013601",
"about": {
"@type": "MedicalCondition",
"name": "Lymphocytes T",
"code": {
"@type": "MedicalCode",
"code": "D013601",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A15.382.490.555.567.569"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lymphocytes T CD8+",
"alternateName": "CD8-Positive T-Lymphocytes",
"code": {
"@type": "MedicalCode",
"code": "D018414",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christoph Fraune",
"url": "https://questionsmedicales.fr/author/Christoph%20Fraune",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany."
}
},
{
"@type": "Person",
"name": "Tim Mandelkow",
"url": "https://questionsmedicales.fr/author/Tim%20Mandelkow",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany."
}
},
{
"@type": "Person",
"name": "Martina Kluth",
"url": "https://questionsmedicales.fr/author/Martina%20Kluth",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany."
}
},
{
"@type": "Person",
"name": "Claudia Hube-Magg",
"url": "https://questionsmedicales.fr/author/Claudia%20Hube-Magg",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany."
}
},
{
"@type": "Person",
"name": "Ronald Simon",
"url": "https://questionsmedicales.fr/author/Ronald%20Simon",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. r.simon@uke.de."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36088952",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2352-4642(22)00245-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.",
"datePublished": "2023-10-19",
"url": "https://questionsmedicales.fr/article/37873026",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03085759231203019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.",
"datePublished": "2022-08-27",
"url": "https://questionsmedicales.fr/article/36145549",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/pharmaceutics14091801"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).",
"datePublished": "2024-07-14",
"url": "https://questionsmedicales.fr/article/39029359",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.lungcan.2024.107894"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment.",
"datePublished": "2024-08-20",
"url": "https://questionsmedicales.fr/article/39228724",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/2024.08.20.24312311"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Systèmes sanguin et immunitaire",
"item": "https://questionsmedicales.fr/mesh/D006424"
},
{
"@type": "ListItem",
"position": 3,
"name": "Système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007107"
},
{
"@type": "ListItem",
"position": 4,
"name": "Leucocytes",
"item": "https://questionsmedicales.fr/mesh/D007962"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agranulocytes",
"item": "https://questionsmedicales.fr/mesh/D007963"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lymphocytes",
"item": "https://questionsmedicales.fr/mesh/D008214"
},
{
"@type": "ListItem",
"position": 7,
"name": "Lymphocytes T",
"item": "https://questionsmedicales.fr/mesh/D013601"
},
{
"@type": "ListItem",
"position": 8,
"name": "Lymphocytes T CD8+",
"item": "https://questionsmedicales.fr/mesh/D018414"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lymphocytes T CD8+ - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lymphocytes T CD8+",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lymphocytes T CD8+",
"description": "Comment diagnostiquer une déficience en lymphocytes T CD8+ ?\nQuels tests sont utilisés pour évaluer l'activité des lymphocytes T CD8+ ?\nQuels marqueurs sont associés aux lymphocytes T CD8+ ?\nComment évaluer la réponse immunitaire des lymphocytes T CD8+ ?\nQuel rôle joue la cytométrie en flux dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D018414?mesh_terms=Probability&page=276#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lymphocytes T CD8+",
"description": "Quels symptômes indiquent une dysfonction des lymphocytes T CD8+ ?\nComment une carence en lymphocytes T CD8+ se manifeste-t-elle ?\nLes lymphocytes T CD8+ affectent-ils la fatigue ?\nQuels signes cliniques sont associés à une activation des lymphocytes T CD8+ ?\nLes lymphocytes T CD8+ influencent-ils les symptômes allergiques ?",
"url": "https://questionsmedicales.fr/mesh/D018414?mesh_terms=Probability&page=276#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lymphocytes T CD8+",
"description": "Comment renforcer les lymphocytes T CD8+ par l'alimentation ?\nLe vaccin contre la grippe aide-t-il les lymphocytes T CD8+ ?\nQuels modes de vie favorisent la santé des lymphocytes T CD8+ ?\nLes compléments alimentaires sont-ils bénéfiques ?\nComment éviter les infections pour protéger les lymphocytes T CD8+ ?",
"url": "https://questionsmedicales.fr/mesh/D018414?mesh_terms=Probability&page=276#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lymphocytes T CD8+",
"description": "Quels traitements stimulent les lymphocytes T CD8+ ?\nComment les vaccins affectent-ils les lymphocytes T CD8+ ?\nLes traitements antiviraux influencent-ils les lymphocytes T CD8+ ?\nQuel rôle joue la thérapie génique pour les lymphocytes T CD8+ ?\nLes corticostéroïdes affectent-ils les lymphocytes T CD8+ ?",
"url": "https://questionsmedicales.fr/mesh/D018414?mesh_terms=Probability&page=276#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lymphocytes T CD8+",
"description": "Quelles complications peuvent survenir avec une carence en lymphocytes T CD8+ ?\nLes lymphocytes T CD8+ peuvent-ils causer des maladies auto-immunes ?\nComment une réponse immunitaire inappropriée affecte-t-elle la santé ?\nQuelles sont les conséquences d'une immunothérapie sur les lymphocytes T CD8+ ?\nLes lymphocytes T CD8+ sont-ils impliqués dans le rejet de greffe ?",
"url": "https://questionsmedicales.fr/mesh/D018414?mesh_terms=Probability&page=276#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lymphocytes T CD8+",
"description": "Quels facteurs augmentent le risque de carence en lymphocytes T CD8+ ?\nLe stress chronique affecte-t-il les lymphocytes T CD8+ ?\nLes infections virales influencent-elles les lymphocytes T CD8+ ?\nL'alimentation peut-elle affecter les lymphocytes T CD8+ ?\nLes traitements immunosuppresseurs impactent-ils les lymphocytes T CD8+ ?",
"url": "https://questionsmedicales.fr/mesh/D018414?mesh_terms=Probability&page=276#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en lymphocytes T CD8+ ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un test sanguin pour mesurer le nombre de lymphocytes T CD8+ est effectué."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des lymphocytes T CD8+ ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de prolifération cellulaire et des dosages d'interféron gamma sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux lymphocytes T CD8+ ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs CD8 et CD3 sont typiquement utilisés pour identifier ces lymphocytes."
}
},
{
"@type": "Question",
"name": "Comment évaluer la réponse immunitaire des lymphocytes T CD8+ ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "On peut utiliser des tests de cytotoxicité pour mesurer leur capacité à tuer les cellules cibles."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la cytométrie en flux dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La cytométrie en flux permet de quantifier et de caractériser les lymphocytes T CD8+ dans le sang."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une dysfonction des lymphocytes T CD8+ ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une susceptibilité accrue aux infections virales et aux cancers peut indiquer une dysfonction."
}
},
{
"@type": "Question",
"name": "Comment une carence en lymphocytes T CD8+ se manifeste-t-elle ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des infections récurrentes et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les lymphocytes T CD8+ affectent-ils la fatigue ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une faible activité des lymphocytes T CD8+ peut contribuer à une fatigue chronique."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à une activation des lymphocytes T CD8+ ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes d'inflammation et des symptômes de réponse immunitaire peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les lymphocytes T CD8+ influencent-ils les symptômes allergiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent moduler la réponse immunitaire, mais ne sont pas directement responsables des allergies."
}
},
{
"@type": "Question",
"name": "Comment renforcer les lymphocytes T CD8+ par l'alimentation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants et en vitamines peut soutenir leur fonction."
}
},
{
"@type": "Question",
"name": "Le vaccin contre la grippe aide-t-il les lymphocytes T CD8+ ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il stimule la réponse des lymphocytes T CD8+ contre le virus de la grippe."
}
},
{
"@type": "Question",
"name": "Quels modes de vie favorisent la santé des lymphocytes T CD8+ ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie actif, une bonne hygiène de sommeil et la gestion du stress favorisent leur santé."
}
},
{
"@type": "Question",
"name": "Les compléments alimentaires sont-ils bénéfiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains compléments, comme la vitamine D, peuvent soutenir la fonction des lymphocytes T CD8+."
}
},
{
"@type": "Question",
"name": "Comment éviter les infections pour protéger les lymphocytes T CD8+ ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pratiquer une bonne hygiène, se faire vacciner et éviter les contacts avec des malades aide."
}
},
{
"@type": "Question",
"name": "Quels traitements stimulent les lymphocytes T CD8+ ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les immunothérapies, comme les inhibiteurs de points de contrôle, stimulent leur activité."
}
},
{
"@type": "Question",
"name": "Comment les vaccins affectent-ils les lymphocytes T CD8+ ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccins peuvent induire une réponse des lymphocytes T CD8+ contre des pathogènes spécifiques."
}
},
{
"@type": "Question",
"name": "Les traitements antiviraux influencent-ils les lymphocytes T CD8+ ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements antiviraux peuvent améliorer la fonction des lymphocytes T CD8+."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la thérapie génique pour les lymphocytes T CD8+ ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique peut être utilisée pour modifier les lymphocytes T CD8+ afin de cibler des cancers."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes affectent-ils les lymphocytes T CD8+ ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent inhiber l'activité des lymphocytes T CD8+ et réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une carence en lymphocytes T CD8+ ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves et des cancers peuvent survenir en raison d'une carence."
}
},
{
"@type": "Question",
"name": "Les lymphocytes T CD8+ peuvent-ils causer des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive peut contribuer à des maladies auto-immunes par attaque des tissus."
}
},
{
"@type": "Question",
"name": "Comment une réponse immunitaire inappropriée affecte-t-elle la santé ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des inflammations chroniques et des dommages aux tissus sains."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une immunothérapie sur les lymphocytes T CD8+ ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunothérapie peut provoquer des effets secondaires, comme des réactions auto-immunes."
}
},
{
"@type": "Question",
"name": "Les lymphocytes T CD8+ sont-ils impliqués dans le rejet de greffe ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent reconnaître les cellules étrangères et provoquer un rejet de greffe."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de carence en lymphocytes T CD8+ ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, certaines maladies chroniques et l'immunosuppression augmentent ce risque."
}
},
{
"@type": "Question",
"name": "Le stress chronique affecte-t-il les lymphocytes T CD8+ ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut diminuer leur nombre et leur efficacité."
}
},
{
"@type": "Question",
"name": "Les infections virales influencent-elles les lymphocytes T CD8+ ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme le VIH, peuvent réduire leur nombre et leur fonction."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle affecter les lymphocytes T CD8+ ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation pauvre en nutriments essentiels peut nuire à leur développement et fonction."
}
},
{
"@type": "Question",
"name": "Les traitements immunosuppresseurs impactent-ils les lymphocytes T CD8+ ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent réduire le nombre et l'activité des lymphocytes T CD8+ dans l'organisme."
}
}
]
}
]
}
Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess ...
In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweig...
Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4...
An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not ass...
The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research....
This paper draws on a qualitative interview-based study that explored online mental health and wellbeing interventions and services for care-experienced young people. The study involved young people (...
The World Health Organization recommends pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV infection. The aim of this analysis is to quantify the individual risk of HIV infect...
The risk and survival of patients with non-small cell lung cancer (NSCLC) with pre-existing autoimmune disorders (AIDs) receiving immune checkpoint blockade (ICB) therapy have not been clearly establi...
This multi-institutional, retrospective cohort study was conducted in collaboration with 20 centers in Japan....
In total, 229 patients with advanced or recurrent NSCLC and pre-existing AID, with or without ICB treatment from January 2010-February 2020, were included and analyzed. Among 69 patients who received ...
These findings revealed a novel risk factor for AID flares following ICB treatment, that is the diagnosis of NSCLC within 1 year of AID diagnosis, and showed that ICBs may improve survival in this pop...
Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has impo...
Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Ander...
Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to ...
This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the proba...
This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation....
Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antena...
WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phospha...
This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmaco...
ISRCTN11434567 . Registered on 7 June 2021....